The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab

Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasser, Pascal, Tarchevskaya, Svetlana S., Guntern, Pascal, Brigger, Daniel, Ruppli, Rahel, Zbären, Noemi, Kleinboelting, Silke, Heusser, Christoph, Jardetzky, Theodore S., Eggel, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949303/
https://www.ncbi.nlm.nih.gov/pubmed/31913280
http://dx.doi.org/10.1038/s41467-019-13815-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949303/
https://www.ncbi.nlm.nih.gov/pubmed/31913280
http://dx.doi.org/10.1038/s41467-019-13815-w

Ejemplares similares